Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 29 systematic review(s)/meta-analysis(es). ^[1-29]
• Gastroesophageal Adenocarcinoma (GEA): Ramucirumab (RAM) combined with FOLFIRI or irinotecan achieved an overall response rate (ORR) ranging from 22% to 38%, with a pooled ORR of 25.4%. In combination with paclitaxel, RAM improved median overall survival (mOS) to 9.3-12.2 months and median progression-free survival (mPFS) to 4.1-5.1 months compared to paclitaxel alone (mOS: 5.2-9.7 months, mPFS: 3.0-4.1 months).
• Hepatocellular Carcinoma (HCC): RAM provided progression-free survival benefits (HR = 0.44) similar to regorafenib and cabozantinib, with an overall survival benefit (HR (hazard ratio) = 0.82) over placebo. However, regorafenib and cabozantinib offered greater overall survival (OS) improvements (HR = 0.62 and HR = 0.74, respectively).
• Non-Small Cell Lung Cancer (NSCLC): RAM plus docetaxel achieved a median OS of 11.2 months in patients pretreated with immune checkpoint inhibitors (ICI) and 13.5 months in ICI-naive patients. Median PFS was 5.7 months for ICI-pretreated and 3.8 months for ICI-naive patients.
• EGFR-Mutated NSCLC: RAM combined with erlotinib demonstrated progression-free survival outcomes comparable to osimertinib and dacomitinib, with no significant difference in overall survival among treatments.
• Gastroesophageal Adenocarcinoma (GEA) Safety: For RAM combined with FOLFIRI or irinotecan, neutropenia and diarrhea were the most commonly reported adverse events. In combination with paclitaxel, hematological toxicities were frequent, with low discontinuation rates due to adverse events (3.3-6.3%).
• Hepatocellular Carcinoma (HCC) Safety: Ramucirumab exhibited an established safety profile with no significant new safety concerns, showing consistent safety across patient subgroups.
• EGFR-Mutated NSCLC Safety: RAM combined with erlotinib increased the incidence of serious adverse events, particularly diarrhea, proteinuria, and hypertension, showing a higher risk of serious adverse events compared to erlotinib alone.
• Ramucirumab (RAM) demonstrated higher overall response rates (ORR) in gastroesophageal adenocarcinoma (GEA) patients pretreated with taxanes and improved progression-free survival (mPFS) in patients with prior anti-PD-1 exposure. In hepatocellular carcinoma (HCC), RAM showed effectiveness regardless of elevated AFP levels, and in non-small cell lung cancer (NSCLC), RAM combined with docetaxel had consistent effectiveness and safety across patients, regardless of prior ICI treatment. In EGFR-mutated NSCLC, RAM with erlotinib provided comparable PFS benefits across subgroups, including those with exon 19 deletions and L858R mutations.